Albana Gjyzari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Albana Gjyzari has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Armela Zylfo
Department of Medicine, Barleti University, 1000 Tirana, Albania
1 shared publication Genc Burazeri
Department of Public Health, Faculty of Medicine, University of Medicine, Tirana, Albania; Department of International Health, CAPHRI (Care and Public Health Research Institute), Maastricht University, Maastricht
1 shared publication- Genc Burazeri
Faculty of Medicine, University of Medicine, Tirana, Albania; Department of International Health, CAPHRI (Care and Public Health Research Institute), Maastricht University, Maastricht, the Netherlands
1 shared publication - Gentian Stroni
Faculty of Technical Medical Sciences, University of Medicine, 1005 Tirana, Albania
1 shared publication Jonida Stefa
Department of Preclinical Sciences, Faculty of Technical Medical Sciences, University of Medicine, Tirana
1 shared publication- Jonida Stefa
University of Medicine Tirana, Tirana, Albania
1 shared publication
Latest Publications
- Open Access
- 22 June 2026
- Published by Springer Nature in African Journal of Urology
- Vol. 32 (1) , 48
Mortality and burden of prostate cancer in Albania, 1990–2023: a regional comparison with Southeastern Europe
Background: To assess long-term trends in mortality and disease burden from prostate cancer in Albania during 1990–2023 in comparison to other Southeastern European countries and broader European regions. Materials and methods: An analysis of mortality and morbidity estimates of prostate cancer was conducted based on data available from the Global Burden of Disease (GBD) studies. Crude and age-standardized mortality rates, proportional mortality, and Disability-Adjusted Life Years (DALYs) of prostate cancer were analysed for Albania. Furthermore, age-standardized estimates of Albania were compared with Southeastern European countries and with Eastern, Central, and Western European regions. Results: From 1990 to 2023, prostate cancer mortality and DALYs in Albania increased modestly in absolute terms, whereas age-standardized rates remained relatively stable. Conversely, proportional mortality and DALYs increased, due to population ageing. Compared with Southeastern Europe, Albania exhibited lower or comparable age-standardized rates, with smaller increases than several neighbouring countries. By 2023, Albania’s prostate cancer burden, which increased modestly since 1990, remained nevertheless the lowest across European regions, despite Western Europe’s sharp decline. Conclusion: Notwithstanding the lowest burden in Europe, prostate cancer in Albania exhibits a growing proportional impact on public health which is a cause of concern. Importantly though, Albania’s lowest prostate cancer mortality and disease burden compared with all European regions may reflect under-reporting, warranting extreme caution in interpreting its comparatively favourable position and highlighting the importance of strengthening cancer surveillance and prevention strategies to ensure accurate monitoring and sustained public health gains.
- 22 June 2026
- Published by Springer Nature in African Journal of Urology
- Vol. 32 (1) , 48
Open AccessMortality and burden of prostate cancer in Albania, 1990–2023: a regional comparison with Southeastern Europe
Background: To assess long-term trends in mortality and disease burden from prostate cancer in Albania during 1990–2023 in comparison to other Southeastern European countries and broader European regions. Materials and methods: An analysis of mortality and morbidity estimates of prostate cancer was conducted based on data available from the Global Burden of Disease (GBD) studies. Crude and age-standardized mortality rates, proportional mortality, and Disability-Adjusted Life Years (DALYs) of prostate cancer were analysed for Albania. Furthermore, age-standardized estimates of Albania were compared with Southeastern European countries and with Eastern, Central, and Western European regions. Results: From 1990 to 2023, prostate cancer mortality and DALYs in Albania increased modestly in absolute terms, whereas age-standardized rates remained relatively stable. Conversely, proportional mortality and DALYs increased, due to population ageing. Compared with Southeastern Europe, Albania exhibited lower or comparable age-standardized rates, with smaller increases than several neighbouring countries. By 2023, Albania’s prostate cancer burden, which increased modestly since 1990, remained nevertheless the lowest across European regions, despite Western Europe’s sharp decline. Conclusion: Notwithstanding the lowest burden in Europe, prostate cancer in Albania exhibits a growing proportional impact on public health which is a cause of concern. Importantly though, Albania’s lowest prostate cancer mortality and disease burden compared with all European regions may reflect under-reporting, warranting extreme caution in interpreting its comparatively favourable position and highlighting the importance of strengthening cancer surveillance and prevention strategies to ensure accurate monitoring and sustained public health gains.
- Open Access
- 12 February 2026
- Published by PAGEPress Publications in Healthcare in Low-resource Settings
- Vol. 14 (1)
Psychometric validation of the EORTC QLQ-PR25 and clinical correlates of quality of life among Albanian men with prostate cancer
Our aim was to assess the psychometric properties of the “EORTC QLQ-PR25” in Albania and to determine the links between disease characteristics and treatment in men with prostate cancer. A study conducted in Tirana during April 2024–December 2025 included 74 consecutive men diagnosed with prostate cancer who completed the EORTC QLQ-PR25 questionnaire (response: ≈94%). The EORTC QLQ-PR25 demonstrated excellent internal consistency across all subscales (Cronbach’s alpha range: 0.85-0.91), with very high reliability for the overall scale (α=0.94). Higher symptom burden and poorer overall quality-of-life were significantly associated with radical prostatectomy, metastatic disease, high Gleason score (9-10), and extracapsular tumour spread (all P<0.05). Patients undergoing radical prostatectomy reported the worst outcomes across all symptom domains, as well as the lowest general quality-of-life and health status scores. Seemingly, the EORTC QLQ-PR25 is a reliable and clinically valid instrument for assessing prostate cancer-specific quality-of-life among Albanian men. Also, symptom burden and quality-of-life impairment were strongly associated with disease severity and invasive treatment. Our findings support the integration of patient-reported outcomes into routine prostate cancer care in Albanian-speaking countries.
- 12 February 2026
- Published by PAGEPress Publications in Healthcare in Low-resource Settings
- Vol. 14 (1)
Open AccessPsychometric validation of the EORTC QLQ-PR25 and clinical correlates of quality of life among Albanian men with prostate cancer
Our aim was to assess the psychometric properties of the “EORTC QLQ-PR25” in Albania and to determine the links between disease characteristics and treatment in men with prostate cancer. A study conducted in Tirana during April 2024–December 2025 included 74 consecutive men diagnosed with prostate cancer who completed the EORTC QLQ-PR25 questionnaire (response: ≈94%). The EORTC QLQ-PR25 demonstrated excellent internal consistency across all subscales (Cronbach’s alpha range: 0.85-0.91), with very high reliability for the overall scale (α=0.94). Higher symptom burden and poorer overall quality-of-life were significantly associated with radical prostatectomy, metastatic disease, high Gleason score (9-10), and extracapsular tumour spread (all P<0.05). Patients undergoing radical prostatectomy reported the worst outcomes across all symptom domains, as well as the lowest general quality-of-life and health status scores. Seemingly, the EORTC QLQ-PR25 is a reliable and clinically valid instrument for assessing prostate cancer-specific quality-of-life among Albanian men. Also, symptom burden and quality-of-life impairment were strongly associated with disease severity and invasive treatment. Our findings support the integration of patient-reported outcomes into routine prostate cancer care in Albanian-speaking countries.